Health News Releases

May 17, 2019 08:52

SpinalCyte Launches Initiative to Highlight Advances in Fibroblast Technology

SpinalCyte, LLC, a clinical stage regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced a new comprehensive resource to raise awar

May 16, 2019 19:49

Trial results of Pradaxa® vs ASA in ESUS published in NEJM

Boehringer Ingelheim today announced full results from the RE-SPECT ESUS® trial, a Phase III randomised, double-blind study investigating the efficacy and safety of Pradaxa® (dabigatran etexilate) ver

May 16, 2019 10:45

Q3 Medical Devices Limited Enters into a Distribution Agreement with Medtronic for its Biodegradable Biliary and Pancreatic Stent

Q3 Medical Devices Limited (“Q3 Medical”) based in Dublin, Ireland, announced today that it has entered into a distribution agreement with Medtronic plc for ARCHIMEDES, the first to market fully biode

May 16, 2019 08:51

LifeArc and GVK BIO Celebrate a Decade of Partnership, Transforming Research into Life-Saving Medicines

GVK BIO, a leading global Contract Research and Development Organisation (CRDO), and LifeArc, one of UK’s top medical research charities, are pleased to announce the 10th anniversary of a successful p

May 15, 2019 17:15

Takeda to Highlight New Research into the Long-term Complications of Chronic Hypoparathyroidism at the European Congress of Endocrinology 2019 Annual Meeting

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will feature 7 presentations, including one oral presentation, at the upcoming European Congress of Endocri

May 15, 2019 11:55

SpeeDx Receives Clearance for PlexPCR Respiratory Virus Test

SpeeDx Pty. Ltd. today announced the clearance of the PlexPCR® RespiVirus* test from the Australian Therapeutic Goods Administration (TGA). The test utilises market-leading PlexPCR® technology to dete

May 14, 2019 10:15

Masimo and Mindray Announce Expanded Partnership

Masimo (NASDAQ: MASI) and Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE: 300760) announced today that they have entered into a purchase and license agreement, under which Mindray will offer

May 14, 2019 08:50

TRIGR Therapeutics Announces Formation of Global Clinical & Scientific Advisory Board

TRIGR Therapeutics, Inc. (“TRIGR”), a clinical stage biotechnology company focused on the development of multi-targeted and immunomodulatory bispecific antibodies, announced today the formation of its

May 10, 2019 13:16

Takeda Expands Oncology Research, Demonstrating Commitment to Patient Community at 15th International Symposium on Myelodysplastic Syndromes

Takeda Pharmaceutical Company Limited [TSE: 4502 / NYSE: TAK] today announced that it will present a total of five company-sponsored poster presentations, as well as an oral pipeline symposium, at the

May 10, 2019 09:27

U.S. Food & Drug Administration Accepts Takeda’s Biologics License Application for a Subcutaneous Formulation of Vedolizumab (Entyvio®) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for a

May 09, 2019 10:24

Takeda Simplifies Portfolio and Accelerates Deleveraging Through Two Divestitures

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into agreements to divest its Xiidra® (lifitegrast ophthalmic solution) 5% product (“Xiidra®”)

May 08, 2019 09:20

Analysis Showed Oral Ozanimod Reduced Brain Volume Loss Across All Age Subgroups in Adults with Relapsing Multiple Sclerosis

Celgene Corporation (NASDAQ:CELG) today announced the results of a post-hoc analysis of data from the Phase 3 RADIANCE™ Part B trial showing that ozanimod reduced cortical grey matter volume loss vers

May 03, 2019 16:40

Apax Funds, CPPIB and PSP Investments Agree to Sell Acelity and its KCI Subsidiaries to 3M for $6.725 Billion

A consortium comprised of funds advised by Apax Partners (the “Apax Funds”), together with Canada Pension Plan Investment Board (“CPPIB”) and the Public Sector Pension Investment Board (“PSP Investmen

April 30, 2019 17:30

Eyenuk’s AI Eye Screening System For Diabetic Retinopathy Demonstrates Exceptional Performance In A Prospective, Multi-Center, Pivotal Clinical Trial

Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today results from its landmark p

April 30, 2019 15:00

tHIS 2019 to Shape Future Health Science and Technology With Expanded Exhibition Scale in Shanghai and Hangzhou

The Health Industry Summit (tHIS) 2019, organized by Reed Sinopharm, will scale up with a total exhibition area of 400,000m2. For the first time, it will adopt the “Two Cities One Show” mode - to be l

April 30, 2019 14:00

Hospitals in Taiwan Make a Commitment to Eliminate Preventable Patient Harm & Death in Hospitals

The Patient Safety Movement Foundation (PSMF) and the Taiwan Patient Safety Culture Club (TPSCC) announced today that 4 hospitals and 1 healthcare organization made a public commitment to helping elim

April 30, 2019 11:50

Masimo Announces First CE-marked Third-party Masimo Open Connect® Module for the Root® Patient Monitoring and Connectivity Hub

Masimo (NASDAQ: MASI) and Mdoloris Medical Systems announced today the CE marking of the Mdoloris Analgesia Nociception Index (ANI®) module for the Masimo Root® Patient Monitoring and Connectivity Hub

April 29, 2019 09:45

Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA

April 25, 2019 17:10

USD$90 Million Initiative between A*Star, Aptorum Group and Aeneas Capital to Drive Healthcare Innovations

Aptorum Group Limited (Nasdaq: APM), Aeneas Capital Limited, and A*ccelerate Technologies Pte Ltd, the enterprise office of the Agency for Science, Technology and Research (A*STAR), have signed a USD$

April 24, 2019 18:05

Aptorum Group Limited Announces Repurchase of USD13,500,000 Outstanding Convertible Bonds Due 2019

Aptorum Group Limited (NASDAQ: APM) (“Aptorum” or the “Company”), a pharmaceutical company focused on the development and commercialization of therapeutic and diagnostic technologies to tackle unmet m

April 24, 2019 17:30

Aptorum Group’s Smart Pharma announces launch of its asset backed Smart Pharma token (SMPT), supported by its computational repurposed drug discovery platform Smart-ACT™

Aptorum Group Limited (Nasdaq:APM) is excited to announce the launch and issuance of its asset backed Smart Pharma Token (“SMPT”) by its wholly owned subsidiary group, Smart Pharma group and Smart Pha

April 24, 2019 17:30

Aptorum Group establishes Smart Pharma to Focus on Computational Repurposed Drug Discovery for Orphan and unmet Diseases

Aptorum Group Limited (Nasdaq: APM) today announced the establishment of a new subsidiary group, Smart Pharma (“SmartP”), which operates its novel computational repurposed drug discovery, modeling and

April 23, 2019 13:50

Infraredx, a Nipro Company, Announces FDA Approval of Expanded Label Claim for the Makoto™ Intravascular Imaging System

Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FD

April 23, 2019 00:00

Comprehensive Tumor Profiling Promises New Therapeutic Options for Patients with Advanced Cancer

Published in Nature Medicine* today, results of WINTHER, the first study pioneered by the WIN Consortium** - - Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

April 19, 2019 13:30

KCI Files Registration Statement for Proposed Initial Public Offering

Acelity announced today that its affiliate, KCI Holdings, Inc. (“KCI”), filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”), relating to a proposed init

News by Region

News by Industry